Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

July 29, 2021
FibroGen to Report Second Quarter 2021 Financial Results
July 19, 2021
Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform
July 15, 2021
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
July 12, 2021
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
June 25, 2021
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
June 17, 2021
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
June 16, 2021
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
May 27, 2021
FibroGen to Present at Upcoming Investor Conferences
May 10, 2021
FibroGen Reports First Quarter 2021 Financial Results
May 3, 2021
FibroGen to Report First Quarter 2021 Financial Results
April 28, 2021
FibroGen to Present at Upcoming Investor Conference
April 15, 2021
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 12, 2021
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 6, 2021
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
April 6, 2021
FibroGen Provides Additional Information on Roxadustat
March 16, 2021
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
March 1, 2021
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
March 1, 2021
FibroGen Provides Regulatory Update on Roxadustat
February 18, 2021
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
February 12, 2021
FibroGen to Present at Upcoming Investor Conferences

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com
Media Inquiries:
GCI Health
FibroGenMedia@gcihealth.com

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
Contact Us

Focus Areas

Our Expertise
Anemia
Idiopathic Pulmonary Fibrosis
Pancreatic Cancer
Duchenne Muscular Dystrophy
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Notice

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2021 FibroGen, Inc.
409 Illinois Street, San Francisco, CA 94158